Early Breast Cancer Trialist's Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365: 1687–1717, 2005.
2.
ChiaS., BryceC., GelmonK.: The 2000 EBCTCG overview: a widening gap. Lancet, 365: 1665–1666, 2005.
3.
Quindici anni di successi per la terapia adiuvante. Onco News, 3 (maggio-giugno): 4, 2005.
4.
Adjuvant therapy for breast cancer. NIH Consensus Statement Online, 17(4): 1–23, November 1-3, 2000.
5.
Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and citotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28.896 women. N Engl J Med, 319: 1681–1692, 1988.
6.
Early Breast Cancer Trialists' Collaborative Group: Polichemotherapy for early breast cancer: an overview of the randomized trials. Lancet, 352: 930–942, 1998.
7.
MustacchiG., CazzanigaM.E., PronzatoP.: Diagnosis and treatment variations in old women with early breast cancer: results from the ‘NORA’ study. Ann Oncol, Suppl 3: ii59 (abs 225P), 2004.
8.
MustacchiG., CazzanigaM.E., PronzatoP.: Different CMF regimens does not lead to adequate dose-intensity in breast cancer adjuvant treatment in older patients. Results from the NORA study. Proc ECCO, 13: abst 356, 2005.
9.
CocconiG.: Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens. Breast Cancer Res Treat, 80: 313–320, 2003.
10.
De MatteisA., CazzanigaM.E., MustacchiG.: Peculiarities of adjuvant treatment in young patients with early breast cancer: results from the ‘NORA’ study. Ann Oncol, Suppl 3: ii67 (abs 254P), 2004.
11.
BonadonnaG., MoliterniA., ZambettiM.: 30 years' follow-up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 330: 217, 2005.
